Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19018731 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18764507 | SULFORAPHANE-CYSTEINE FOR WOUND HEALING IN DIABETIC SUBJECTS | July 2024 | November 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18375745 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | October 2023 | April 2025 | Allow | 18 | 0 | 0 | Yes | No |
| 18180398 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | March 2023 | May 2025 | Allow | 26 | 0 | 1 | Yes | No |
| 18083502 | COMPOSITION FOR PROMOTING NORMAL URINARY FUNCTION | December 2022 | February 2025 | Allow | 26 | 0 | 0 | Yes | No |
| 17967676 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | October 2022 | November 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17967383 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | October 2022 | May 2025 | Allow | 31 | 1 | 0 | No | No |
| 17818083 | COMPOSITION FOR TREATING HAIR LOSS OR PROMOTING HAIR GROWTH, COMPRISING PIPERONYLIC ACID | August 2022 | May 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17875679 | PHARMACEUTICAL COMPOSITION FOR REDUCING LOCAL FAT AND USES THEREOF | July 2022 | March 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17832058 | CITRULLINE FOR TREATMENT OF SICKLE CELL CRISIS | June 2022 | February 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 17782534 | USE OF FGFR INHIBITORS FOR TREATMENT OF IDIOPATHIC SHORT STATURE | June 2022 | May 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17778802 | PROPHYLACTIC SKIN TREATMENT FOR RADIATION THERAPY | May 2022 | May 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17777734 | CANNABIDIOL-TYPE CANNABINOID COMPOUND | May 2022 | April 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17777681 | CANNABIDIOL-TYPE CANNABINOID COMPOUND | May 2022 | April 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17777677 | CANNABIDIOL-TYPE CANNABINOID COMPOUND | May 2022 | March 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17776222 | OLEIC ACID DERIVATIVES AS TREATMENTS FOR FRIEDREICH ATAXIA AND INHIBITORS OF FERROPTOSIS | May 2022 | March 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17666324 | MORE POTENT AND LESS TOXIC FORMULATIONS OF EPINEPHRINE AND METHODS OF MEDICAL USE | February 2022 | December 2024 | Allow | 34 | 1 | 0 | No | No |
| 17568477 | TRIPLE COMBINATION FORMULATION FOR TREATMENT OF CHRONIC PAIN | January 2022 | December 2024 | Abandon | 35 | 3 | 1 | No | No |
| 17305510 | COMPOSITIONS FOR PREVENTING AND TREATING DIABETES | July 2021 | January 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17359272 | COMPOSITION AND METHOD FOR TREATING AUTISM SPECTRUM DISORDER (ASD) SYMPTOMS OF PARANOIA WITH SELF ISOLATION AND/OR AGGRESSION | June 2021 | October 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17180991 | METHODS OF TREATING IDIOPATHIC HYPERSOMNIA | February 2021 | September 2024 | Allow | 43 | 3 | 0 | No | No |
| 17128458 | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | December 2020 | July 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17099224 | ENTHESIS HEALING | November 2020 | June 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 16324353 | THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES | February 2019 | September 2024 | Allow | 60 | 5 | 2 | Yes | Yes |
| 16239719 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | January 2019 | March 2019 | Allow | 2 | 0 | 0 | No | No |
| 16310641 | COMPRESSED CAPSULES FOR GIVING BIRTH TO MALES | December 2018 | July 2019 | Allow | 6 | 0 | 0 | No | No |
| 16191243 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | November 2018 | September 2019 | Allow | 11 | 0 | 1 | No | No |
| 16095282 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | October 2018 | September 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16163108 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | October 2018 | January 2025 | Abandon | 60 | 6 | 0 | No | Yes |
| 16111884 | MONONUCLEOTIDE-DITHIOCARBAMATE COMPLEX | August 2018 | January 2019 | Allow | 5 | 0 | 0 | No | No |
| 16112426 | GOLD COMPLEX-CONTAINING CANCER ACTIVITY COMPOSITION | August 2018 | February 2019 | Allow | 5 | 0 | 0 | No | No |
| 16112358 | CANCER CELL-CONTAINING COMPOSITION | August 2018 | January 2019 | Allow | 4 | 0 | 0 | No | No |
| 16112188 | DNA/DITHIOCARBAMATO PHOSPHINE METAL COMPLEX | August 2018 | February 2019 | Allow | 6 | 0 | 0 | No | No |
| 16107087 | ARGINASE INHIBITORS AS THERAPEUTICS | August 2018 | November 2019 | Allow | 15 | 1 | 0 | No | No |
| 15993163 | GOLD COMPLEXES OF ALKYLATED PHOSPHINES | May 2018 | August 2018 | Allow | 2 | 0 | 0 | No | No |
| 15990289 | COMPOSITION CONTAINING A GOLD (I) COMPLEX AND CANCER CELLS | May 2018 | August 2018 | Allow | 3 | 0 | 0 | No | No |
| 15952875 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF CHRONIC PAIN | April 2018 | November 2018 | Allow | 7 | 1 | 0 | No | No |
| 15767756 | C-3 NOVEL TRITERPENONE WITH C-28 UREA DERIVATIVES AS HIV INHIBITORS | April 2018 | January 2020 | Allow | 21 | 1 | 0 | Yes | No |
| 15951154 | ENHANCED SMOKABLE THERAPEUTIC CANNABIS PRODUCT AND METHOD FOR MAKING SAME | April 2018 | November 2018 | Allow | 7 | 1 | 0 | No | No |
| 15904265 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | February 2018 | March 2019 | Allow | 12 | 1 | 1 | No | No |
| 15783510 | METHODS AND COMPOSITIONS FOR TREATING PAIN | October 2017 | March 2019 | Allow | 17 | 1 | 0 | No | No |
| 15680819 | MEDICAMENT FOR THE TREATMENT OF VIRAL SKIN AND TUMOUR DISEASES | August 2017 | July 2019 | Allow | 22 | 1 | 1 | No | No |
| 15449723 | NOVEL CHOLINE COCRYSTAL OF EPALRESTAT | March 2017 | June 2019 | Allow | 28 | 3 | 1 | Yes | No |
| 15432616 | 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury | February 2017 | January 2019 | Allow | 23 | 1 | 1 | No | No |
| 15328304 | CURCUMIN-SOPHOROLIPID COMPLEX | January 2017 | December 2017 | Allow | 11 | 0 | 1 | Yes | No |
| 15385248 | METHODS OF TREATING LIVER DISEASES | December 2016 | April 2018 | Allow | 16 | 1 | 0 | No | No |
| 15383245 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | December 2016 | December 2017 | Allow | 12 | 0 | 1 | No | No |
| 15351585 | MIXED LIGAND GOLD(I) COMPLEXES AS ANTI-CANCER AGENTS | November 2016 | May 2018 | Allow | 18 | 1 | 2 | No | No |
| 15301127 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS MONOAMINE OXIDASE SELECTIVE ISOFORM B INHIBITORS (As Amended) | September 2016 | November 2018 | Allow | 26 | 0 | 1 | No | No |
| 15076004 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS | March 2016 | December 2016 | Allow | 8 | 0 | 0 | No | No |
| 14780239 | INFANT FORMULA WITH A LOW CONTENT OF MCFAS IN SPECIFIC PROPORTIONS AND A RELATIVELY HIGH CONTENT OF UNSATURATED FATTY ACIDS, AND ITS USE IN PROMOTING THE HEALTHY ESTABLISHMENT OF COGNITIVE FUNCTION IN INFANTS | September 2015 | August 2017 | Allow | 22 | 2 | 1 | No | No |
| 14758724 | CYP450 Lipid Metabolites Reduce Inflammation and Angiogenesis | June 2015 | May 2017 | Allow | 23 | 2 | 1 | Yes | No |
| 14649272 | USE OF CAPSAZEPINE AND ANALOGS THEREOF TO TREAT CANCER | June 2015 | September 2016 | Allow | 15 | 1 | 0 | No | No |
| 14647740 | USE AND APPLICATION REGIMEN OF A PHARMACEUTICAL COMPOSITION CONTAINING LEVONORGESTREL AND A COX INHIBITOR FOR ON-DEMAND CONTRACEPTION | May 2015 | November 2016 | Allow | 18 | 1 | 1 | No | No |
| 14647633 | POWDEROUS FORMULATION | May 2015 | October 2017 | Allow | 29 | 3 | 0 | No | Yes |
| 14440724 | METHODS OF TREATING LIVER DISEASES | May 2015 | September 2016 | Allow | 17 | 1 | 0 | No | No |
| 14437678 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | April 2015 | February 2017 | Allow | 22 | 2 | 0 | Yes | No |
| 14679559 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | April 2015 | March 2018 | Allow | 35 | 2 | 1 | Yes | No |
| 14502422 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | September 2014 | November 2016 | Allow | 26 | 2 | 0 | No | No |
| 14277429 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | May 2014 | March 2016 | Allow | 22 | 1 | 0 | No | No |
| 14179862 | MULTIPLE-COMPONENT SOLID PHASES CONTAINING AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT | February 2014 | July 2017 | Abandon | 41 | 4 | 0 | No | Yes |
| 14153885 | METHOD OF TREATING MICROBIAL INFECTIONS | January 2014 | May 2016 | Allow | 28 | 1 | 0 | No | No |
| 14099882 | METHODS FOR TREATING DEPENDENCE | December 2013 | June 2019 | Allow | 60 | 5 | 1 | Yes | Yes |
| 14002249 | PROTEASOME INHIBITOR DELANZOMIB FOR USE IN THE TREATMENT OF LUPUS | August 2013 | January 2016 | Allow | 28 | 1 | 0 | No | No |
| 13966546 | METHODS AND COMPOSITIONS FOR TREATING PAIN | August 2013 | July 2017 | Allow | 47 | 2 | 1 | No | No |
| 13926653 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF | June 2013 | October 2013 | Allow | 4 | 0 | 0 | Yes | No |
| 13855311 | MULTIFUNCTIONAL QUINOLINE DERIVATIVES AS ANTI-NEURODEGENERATIVE AGENTS | April 2013 | January 2016 | Allow | 34 | 1 | 1 | Yes | No |
| 13520675 | METHODS OF TREATING CANCER USING A COMBINATION OF AN IMMUNOMODULATORY COMPOUND AND AN ARTEMISININ OR A DERIVATIVE THEREOF | February 2013 | August 2015 | Allow | 38 | 1 | 1 | No | No |
| 13669353 | TREATMENT OF DEPRESSIVE DISORDERS | November 2012 | March 2018 | Allow | 60 | 4 | 1 | No | No |
| 13520150 | HEDGEHOG INHIBITORS | September 2012 | May 2015 | Allow | 34 | 1 | 1 | Yes | No |
| 13617035 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | September 2012 | August 2014 | Allow | 23 | 0 | 1 | No | No |
| 13602239 | PYRIDOPYRAZINDIONE DERIVATIVE AND ITS USE AS AN ANTIULCER DRUG | September 2012 | March 2013 | Allow | 6 | 0 | 1 | No | No |
| 13595622 | DINITROPYRAZOLE DERIVATIVES, THEIR PREPARATION, AND ENERGETIC COMPOSITIONS COMPRISING THEM | August 2012 | December 2012 | Allow | 3 | 0 | 0 | No | No |
| 13590061 | ORAL CONTROLLED RELEASE DOSAGE FORM | August 2012 | June 2016 | Allow | 46 | 5 | 0 | Yes | No |
| 13444213 | METHODS AND COMPOSTIONS FOR TREATING PAIN | April 2012 | May 2013 | Allow | 13 | 0 | 0 | No | No |
| 13321046 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | February 2012 | September 2015 | Allow | 46 | 3 | 1 | Yes | No |
| 13264055 | COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF CALCIUM RELEASE CHANNELS | January 2012 | September 2014 | Allow | 35 | 1 | 1 | No | No |
| 13327093 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | December 2011 | July 2012 | Allow | 7 | 0 | 0 | No | No |
| 13294624 | METHODS OF TREATING CANCER | November 2011 | October 2014 | Allow | 35 | 1 | 1 | No | No |
| 13293849 | Antiviral Drugs for Treatment of Arenavirus Infection | November 2011 | June 2014 | Allow | 31 | 1 | 1 | No | No |
| 13222662 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | August 2011 | September 2012 | Allow | 13 | 1 | 0 | Yes | No |
| 13199385 | Nutritional supplement composition promoting, increase, development, elevation and activation of "serotonin" | August 2011 | July 2014 | Allow | 35 | 1 | 0 | Yes | No |
| 13207779 | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | August 2011 | July 2014 | Allow | 35 | 2 | 1 | No | No |
| 13206750 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | August 2011 | November 2014 | Allow | 39 | 1 | 1 | No | No |
| 12810565 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF | May 2011 | March 2013 | Allow | 33 | 0 | 0 | No | No |
| 13124883 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | May 2011 | June 2015 | Allow | 50 | 3 | 1 | Yes | No |
| 12743306 | MECHANISM-BASED SMALL-MOLECULE PARASITE INHIBITORS | March 2011 | March 2013 | Allow | 34 | 0 | 1 | Yes | No |
| 13056201 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DIABETES, OBESITY, DYSLIPIDEMIA OR METABOLIC SYNDROME COMPRISING BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | January 2011 | February 2012 | Allow | 13 | 1 | 0 | No | No |
| 12982785 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | December 2010 | February 2012 | Allow | 13 | 2 | 0 | Yes | Yes |
| 12988951 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | December 2010 | June 2014 | Allow | 44 | 2 | 1 | Yes | No |
| 12958899 | COMPOSITIONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV | December 2010 | July 2014 | Allow | 44 | 1 | 1 | No | No |
| 12528208 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | November 2010 | September 2012 | Allow | 37 | 0 | 0 | Yes | No |
| 12295497 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | November 2010 | August 2013 | Allow | 58 | 2 | 1 | Yes | No |
| 12917669 | DEAZAPURINES AND USES THEREOF | November 2010 | November 2013 | Allow | 37 | 2 | 0 | No | No |
| 12915689 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF CELL STRESS RESPONSE | October 2010 | May 2013 | Allow | 31 | 1 | 1 | Yes | No |
| 12912325 | ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | October 2010 | August 2013 | Allow | 33 | 1 | 0 | No | No |
| 12911244 | KAPPA OPIOID RECEPTOR LIGANDS | October 2010 | January 2012 | Allow | 15 | 1 | 1 | Yes | No |
| 12740912 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | August 2010 | September 2014 | Allow | 53 | 2 | 1 | No | No |
| 12839245 | COMPOSITION AND METHOD OF TREATING HEARING LOSS | July 2010 | June 2011 | Allow | 11 | 1 | 0 | No | No |
| 12681485 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | July 2010 | December 2012 | Allow | 32 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JAVANMARD, SAHAR.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner JAVANMARD, SAHAR works in Art Unit 1622 and has examined 161 patent applications in our dataset. With an allowance rate of 97.5%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner JAVANMARD, SAHAR's allowance rate of 97.5% places them in the 92% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by JAVANMARD, SAHAR receive 1.45 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by JAVANMARD, SAHAR is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +4.5% benefit to allowance rate for applications examined by JAVANMARD, SAHAR. This interview benefit is in the 28% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 39.5% of applications are subsequently allowed. This success rate is in the 88% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 68.8% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 83% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 81.8% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 77.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 43.9% are granted (fully or in part). This grant rate is in the 47% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 12.4% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.